These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [To facilitate the compliance of phosphate binder for the control of hyperphosphatemia in chronic kidney disease patients]. Maruyama T; Kadowaki D Clin Calcium; 2009 Feb; 19(2):248-52. PubMed ID: 19182367 [TBL] [Abstract][Full Text] [Related]
7. Lanthanum carbonate as a first-line phosphate binder: the "cons". Drüeke TB Semin Dial; 2007; 20(4):329-32. PubMed ID: 17635823 [TBL] [Abstract][Full Text] [Related]
9. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Mehrotra R; Martin KJ; Fishbane S; Sprague SM; Zeig S; Anger M; Clin J Am Soc Nephrol; 2008 Sep; 3(5):1437-45. PubMed ID: 18579668 [TBL] [Abstract][Full Text] [Related]
10. [Use of phosphate binder in predialysis patients]. Taniguchi M Clin Calcium; 2009 Feb; 19(2):229-35. PubMed ID: 19182364 [TBL] [Abstract][Full Text] [Related]
11. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis. Shigematsu T; Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515 [TBL] [Abstract][Full Text] [Related]
12. [Efficacy and safety of lanthanum carbonate in chronic kidney disease patients with hyperphosphataemia]. Laville M Nephrol Ther; 2011 Jun; 7(3):154-61. PubMed ID: 21247818 [TBL] [Abstract][Full Text] [Related]
13. [Management of phosphate in chronic kidney disease--Chemistry and history of phosphate binder]. Koiwa F; Sato Y Clin Calcium; 2009 Feb; 19(2):198-204. PubMed ID: 19182359 [TBL] [Abstract][Full Text] [Related]
14. Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China. Xu J; Zhang YX; Yu XQ; Liu ZH; Wang LN; Chen JH; Fan YP; Ni ZH; Wang M; Yuan FH; Ding GH; Chen XM; Zhang AP; Mei CL BMC Nephrol; 2013 Feb; 14():29. PubMed ID: 23379590 [TBL] [Abstract][Full Text] [Related]
15. Lanthanum phosphate binder-induced iron deficiency anaemia. Awad C; Gilkison K; Shaw E BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30878952 [TBL] [Abstract][Full Text] [Related]
16. [Introduction to lanthanum carbonate: pharmacology, safety and tolerability]. Rodríguez Portillo M Nefrologia; 2008; 28 Suppl 5():7-10. PubMed ID: 18847413 [TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate. Damment SJ; Pennick M Clin Pharmacokinet; 2008; 47(9):553-63. PubMed ID: 18698878 [TBL] [Abstract][Full Text] [Related]
19. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Sprague SM Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307 [TBL] [Abstract][Full Text] [Related]
20. A 47-Year-Old Man with Hyperphosphatemia Due to Chronic Renal Failure Treated with Lanthanum Carbonate Tablets Presenting Acutely with Partial Large Bowel Obstruction. Zhou Q; Yu M; Chang X; Shang S; Li M; Xu W Am J Case Rep; 2023 Nov; 24():e942113. PubMed ID: 37994013 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]